TPW:GETTEXTrupanion, Inc. Analysis

TPW is trading at €19, just above its 20‑day SMA (19.01) but well below the 50‑day (20.94) and 200‑day (28.77) averages, indicating a lingering bearish bias. The RSI sits at 43, suggesting neither overbought nor oversold conditions, while the MACD histogram turned positive and the MACD line crossed above its signal, a modest bullish signal. Volume is on an increasing trend, supporting the technical upside potential toward the nearby resistance at €20.80. However, the 30‑day volatility of 52% and a low average daily volume raise concerns about price swings and liquidity. Fundamentally, revenue grew 12.3% year‑over‑year to $1.48 bn, but margins remain thin (gross 22%, operating 1.2%) and free cash flow is negative. The trailing PE of 37.3 far exceeds the industry average of 17, signaling overvaluation on a price‑multiple basis.
By contrast, the discounted cash‑flow model values the company at roughly $37.5 per share, implying a substantial intrinsic upside relative to the current price. The balance sheet is strong, with $384 m cash versus $109 m debt, yielding a modest net‑cash position and a debt‑to‑equity of 27.7%. The low beta of 0.44 suggests limited market‑wide correlation, while the subscription pet‑insurance model provides recurring revenue across North America, Europe and Australia. No dividend is paid, and free cash flow remains negative, indicating limited near‑term return‑of‑capital to shareholders. Overall, the mix of technical support, attractive DCF gap, and solid cash position points to upside, but thin profitability and high volatility temper expectations. Investors should weigh the upside potential against liquidity constraints and the need for the company to convert growth into sustainable earnings.